
Strong FY22 results and a positive start to FY23
15/05/2023 Instem plc
Instem’s FY22 results demonstrate the benefits of the strategic acquisitions made during 2021. Revenue growth was an impressive […]

Impressive growth in FY22
31/01/2023 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2022, reporting c.28% revenue growth […]

Major license fee underpins full-year result
22/12/2022 Instem plc
Instem has announced a major contract extension with an existing customer for its Provantis study management software. The […]

Another positive period for Instem
27/09/2022 Instem plc
Instem has once again delivered a strong set of interim results, in our view, with the outcome consistent […]

Largest ever contract validates growth strategy
05/09/2022 Instem plc
Instem has signed its largest ever single contract, a five-year $12m deal with a leading global contract research […]

H1 22 – strong trading and positive outlook
04/08/2022 Instem plc
Instem’s update for the six months to 30 June 2022 (H1 22) confirms that the business continues to […]

FY21 Strong financial performance, strategic transformation
26/04/2022 Instem plc
Instem has reported FY21 results consistent with the January trading statement and in line with our forecasts. Despite […]

Bringing drugs to market faster
25/02/2022 Instem plc
Instem offers an opportunity to invest in a business with two specific attractions – (1) The group is […]

Trading in-line, all key metrics improving
26/01/2022 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2021, reporting like-for-like (LFL) revenue […]

Strong organic and acquisitive growth
29/09/2021 Instem plc
Instem has once again delivered a strong set of interim results in our view, with the growth story […]

A strategic move in Switzerland
01/09/2021 Instem plc
Instem has announced the (earnings enhancing) acquisition of PDS Pathology Data Systems Ltd (“PDS”) a Swiss-based life sciences […]

H1 21 trading: strength across the board
19/07/2021 Instem plc
Instem’s update for the six months to 30 June 2021 (H1 21E) confirms that trading was in line […]